Published in final edited form as:

Chem Lett. 2011 ; 40(9): . doi:10.1246/cl.2011.1053.

Palladium-Catalyzed Highly Regioselective C-3 Arylation of Imidazo[1,5-*a*]pyridine

Chunhui Huang, Alexandros Giokaris, and Vladimir Gevorgyan*

Department of Chemistry, University of Illinois at Chicago, 845 W. Taylor St., Chicago, Illinois 60607-7061, USA

Abstract

A direct palladium-catalyzed highly regioselective C-3 arylation of imidazo[1,5-*a*]pyridine with aryl bromides has been developed. This reaction is quite general with respect to the aryl or hetaryl bromide.

N-fused bicyclic heteroarenes have attracted increasing attention due to their unique biological activities and photophysical properties.¹ Among them, imidazo[1,5-*a*]pyridines (2-azaindolizines) have been actively investigated as photo-functional materials,² precursors of *N*-heterocyclic carbenes,³ as well as versatile pharmaceuticals⁴ (e.g., cardiotonic agents,⁵ corticotropin releasing hormone receptors,⁶ HIV-protease inhibitors⁷). Therefore, efficient assembly of functionalized imidazo[1,5-*a*]pyridine derivatives is of high demand. To date, most synthetic efforts were devoted to build the imidazole ring of imidazo[1,5-*a*]pyridine,⁸ largely relying on the Vilsmeier-type cyclization of *N*-2-pyridylmethyl amides.⁹ However, these methods either require multistep syntheses of starting materials or are limited to the particular types of substrates. In contrast, a direct, late-stage modification of imidazo[1,5-*a*]pyridine core is much less studied. Precedented two-step C-3 arylation of imidazo[1,5-*a*]pyridine (**1**) involves its electrophilic bromination in the presence of HOAc/Br₂, followed by the Suzuki cross-coupling reaction of the formed hetaryl bromide **2** with arylboronic acids to produce **3** in good yields (eq 1, route A).^{4a,10}

Recently, aryl-aryl bond formation via transition-metal-catalyzed C–H bond arylation approach achieved enormous progress in both aromatic and heteroaromatic systems.¹¹ However, a direct C–H bond arylation of imidazopyridine **1** is limited to a few examples of cationic Pd-catalyzed C-1 arylation of C-3-substituted imidazo[1,5-*a*]pyridines.¹² To the best of our knowledge, there are no reports on a direct C-3 C–H arylation of **1**. Based on our previous regioselective Pd-catalyzed electrophilic arylation of indolizines,¹³ we envisioned that the structural similarity of imidazo[1,5-*a*]pyridine and indolizine might allow the same type of transformations to occur. Herein, we report an efficient and practical approach towards regioselective C-3 arylation of imidazo[1,5-*a*]pyridine (eq 1, route B).

(1)

First, we tested the cross-coupling reaction of unsubstituted imidazo[1,5-*a*]pyridine (**1**) and 1-bromo-4-nitrobenzene (**4a**). Promisingly, the C-3-arylated product **3a** was formed in 18% NMR yield by using Pd(OAc)₂ catalyst (5 mol %) and Bu₄NOAc (2 equiv) as the base in toluene at 100 °C (Table 1, entry 1). A brief screening of various bases resulted in no improvement of the reaction efficiency (entries 2–4). Remarkably, addition of phosphine ligands, such as triphenylphosphine or tricyclohexylphosphine, dramatically increased the efficiency of the reaction producing **3a** in 86% and 71% yield, respectively (entries 5 and 6). Employment of more electron-rich and sterically bulkier ligands was not beneficial for this transformation (entries 7 and 8). Remarkably, in all cases, no traces of the regioisomeric C-1 arylated product were detected by the GC/MS analyses of crude reaction mixtures.

Next, the scope of the regioselective C-3 arylation¹⁴ of **1** was examined (Table 2). Gratifyingly, it was found that this method is quite efficient and very general. A variety of functional groups, such as nitro (**3a**), F (**3b**), CF₃ (**3d**), OMe (**3f**), ester (**3g**), aldehyde (**3h**) and nitrile (**3i**), were perfectly tolerated under these reaction conditions, producing the corresponding biaryls in good to excellent yields. Remarkably, in all cases, the arylation reactions uniformly gave C-3 arylated imidazo[1,5-*a*]pyridines. Of note, 2-bromonaphthalene (**4j**), as well as heteroaromatic bromides such as 2-bromopyridine (**4k**) and 2-bromothiophene (**4l**), were competent in this reaction to produce C-3-naphthyl- and hetaryl-substituted imidazo[1,5-*a*]pyridines in moderate yields. Interestingly, **3k** was shown to be a good ligand for C-1 arylation of **3f**.¹²

At this point, the exact mechanism of this transformation is unclear. The lack of the kinetic isotope effect ($k_H/k_D = 1.0$ for arylation of **1** and C-3 deuterated analogue **1-d**)¹⁵ could suggest an electrophilic pathway.^{13,16} However, since arylation did not occur at the most nucleophilic C-1 position of this heterocycle,¹⁷ a concerted metalation-deprotonation (CMD)¹⁸ pathway could be responsible for the observed regiochemistry.

In summary, we developed a highly regioselective Pd-catalyzed C-3 arylation of imidazopyridine **1** with aryl- and hetaryl bromides. This method allows for rapid preparation of C-3 arylated imidazo[1,5-*a*]pyridines.¹⁹

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support of National Institutes of Health (Grant GM-64444) is gratefully acknowledged.

References and Notes

1. Joule, JA.; Mills, K., editors. *Heterocyclic Chemistry*. 4th ed.. Blackwell Science; Oxford, U.K.: 2000. Chap. 25
2. a) Nakatsuka M, Shimamura T. Jpn. Kokai Tokkyo Koho 2001035664. 2001b) Nakamura H, Yamamoto H. PCT Int. Appl. WO 2005043630. 2005
3. Alcarazo M, Roseblade SJ, Cowley AR, Fernandez R, Brown JM, Lassaletta JM. *J. Am. Chem. Soc.* 2005; 127:3290. [PubMed: 15755141]
4. a) Wu Z, Green AI, Hartnett JC. PCT Int. Appl. WO 2009025785. 2009b) Kimura K, Tsuchiya E, Shibahara F, Murai T. Jpn. Kokai Tokkyo Koho 2008105963. 2008c) Ford NF, Browne LJ, Campbell T, Gemenden C, Goldstein R, Gude C, Wasley JWF. *J. Med. Chem.* 1985; 28:164. [PubMed: 3918169]
5. Davey D, Erhardt PW, Lumma WC Jr, Wiggins J, Sullivan M, Pang D, Cantor E. *J. Med. Chem.* 1987; 30:1337. [PubMed: 3039131]
6. Hartz RA, Gilligan PJ, Nanda KK, Tebben AJ, Fitzgerald LW, Miller K. *Bioorg. Med. Chem. Lett.* 2002; 12:291. [PubMed: 11814780]
7. a) DeGoey, DA.; Flentge, CA.; Flosi, WJ.; Grampovnik, DJ.; Kempf, DJ.; Klein, LL.; Yeung, MC.; Randolph, JT.; Wang, XC.; Yu, S. U.S. Patent 20050148623. 2005. b) Kim D, Wang L, Hale JJ, Lynch CL, Budhu RJ, MacCoss M, Mills SG, Malkowitz L, Gould SL, DeMartino JA, Springer MS, Hazuda D, Miller M, Kessler J, Hrin RC, Carver G, Carella A, Henry K, Lineberger J, Schleif WA, Emini EA. *Bioorg. Med. Chem. Lett.* 2005; 15:2129. [PubMed: 15808483]
8. a) Sasaki K, Tsurumori A, Hirota T. *J. Chem. Soc., Perkin Trans.* 1998; 1:3851. b) Wang J, Mason R, VanDerveer D, Feng K, Bu XR. *J. Org. Chem.* 2003; 68:5415. [PubMed: 12816512] c) Shibahara F, Kitagawa A, Yamaguchi E, Murai T. *Org. Lett.* 2006; 8:5621. [PubMed: 17107087] d) Bluhm ME, Ciesielski M, Görls H, Döring M. *Angew. Chem., Int. Ed.* 2002; 41:2962. e) Cai Q, Li Z, Wei J, Fu L, Ha C, Pei D, Ding K. *Org. Lett.* 2010; 12:1500. [PubMed: 20196570] f) Chuprakov S, Hwang FW, Gevorgyan V. *Angew. Chem., Int. Ed.* 2007; 46:4757.
9. Bower JD, Ramage GR. *J. Chem. Soc.* 1955:2834.
10. Shibahara F, Yamaguchi E, Kitagawa A, Imai A, Murai T. *Tetrahedron.* 2009; 65:5062.
11. Alberico D, Scott ME, Lautens M. *Chem. Rev.* 2007; 107:174. [PubMed: 17212475] . Campeau L-C, Stuart DR, Fagnou K. *Aldrichimica Acta.* 2007; 40:35.; Seregin IV, Gevorgyan V. *Chem. Soc. Rev.* 2007; 36:1173. [PubMed: 17576484] . Satoh T, Miura M. *Chem. Lett.* 2007; 36:200.. McGlacken GP, Bateman LM. *Chem. Soc. Rev.* 2009; 38:2447. [PubMed: 19623360] . You S-L, Xia J-B, Yu J-Q, Shi Z. *Topics in Current Chemistry.* 2010; Vol. 292:165–194. Springer-Verlag Berlin, Germany.
12. Shibahara F, Yamaguchi E, Murai T. *Chem. Commun.* 2010:2471.
13. Park C-H, Ryabova V, Seregin IV, Sromek AW, Gevorgyan V. *Org. Lett.* 2004; 6:1159. [PubMed: 15040747]
14. The C-3 regioselectivity was further proved by the reaction of 3-deutero-imidazo[1,5-*a*]pyridine **1-d** with **4d**. **3d** was the only product.
15. See Supporting Information for details.
16. Pivsa-Art S, Satoh T, Kawamura Y, Miura M, Nomura M. *Bull. Chem. Soc. Jpn.* 1998; 71:467.. Li W, Nelson DP, Jensen MS, Hoerrner RS, Javadi GJ, Cai D, Larsen RD. *Org. Lett.* 2003; 5:4835. [PubMed: 14653686] . Lane BS, Brown MA, Sames D. *J. Am. Chem. Soc.* 2005; 127:8050. [PubMed: 15926829] . Chiong HA, Daugulis O. *Org. Lett.* 2007; 9:1449. [PubMed: 17358073] . Chuprakov S, Chernyak N, Dudnik AS, Gevorgyan V. *Org. Lett.* 2007; 9:2333. [PubMed: 17489598] . For a recent review, see: Livendahl M, Echavarren AM. *Isr. J. Chem.* 2010; 50:630.. For a proposed Heck-type mechanism with $k_H/k_D \sim 1$, see: Wang J-X, McCubbin JA, Jin M, Laufer RS, Mao Y, Crew AP, Mulvihill MJ, Snieckus V. *Org. Lett.* 2008; 10:2923. [PubMed: 18576663] .
17. a) Bower JD, Ramage GR. *J. Chem. Soc.* 1955:2834. b) Blatcher P, Middlemiss D. *Tetrahedron Lett.* 1980; 21:2195.
18. a) Gorelsky SI, Lapointe D, Fagnou K. *J. Am. Chem. Soc.* 2008; 130:10848. [PubMed: 18661978] b) Potavathi S, Pereira KC, Gorelsky SI, Pike A, LeBris AP, DeBoef B. *J. Am. Chem. Soc.* 2010;

132:14676. [PubMed: 20863119] c) Liegault B, Petrov I, Gorelsky SI, Fagnou K. J. Org. Chem. 2010; 75:1047. [PubMed: 20073523]

19. Supporting Information is available electronically on the CSJ-Journal Web site, <http://www.csj.jp/journals/chem-lett/index.html>

Table 1

Optimization of Reaction Conditions^a

Entry	Ligand	Base	Yield, % ^b
1	N/A	Bu ₄ NOAc	18
2	N/A	Cs ₂ CO ₃	6
3	N/A	AgOAc	17
4	N/A	KOAc	4
5	PPh₃	Bu₄NOAc	86
6	PCy ₃	Bu ₄ NOAc	71
7	TDMPP ^c	Bu ₄ NOAc	7
8	^t Bu ₂ MeP•HBF ₄	Bu ₄ NOAc	28

^a Conditions: imidazo[1,5-*a*]pyridine **1** (1 equiv), *p*-NO₂C₆H₄Br (1 equiv), Pd(OAc)₂ (5 mol%), ligand (10 mol%), base (2 equiv), toluene, 100 °C, 8 h.

^b NMR yield.

^c TDMPP = Tris(2,6-dimethoxyphenyl)phosphine.

Table 2

Arylation scope of Imidazo[1,5-*a*]pyridine^{a,b}

Entry	Product	Entry	Product
1	3a, 90%	7	3g, 50%^d
2	3b, 88%	8	3h, 51%^d
3	3c, 99%	9	3i, 71%^d
4	3d, 86%	10	3j, 46%^d

Entry	Product	Entry	Product
5	3e, 55%^c	11	3k, 48%
6	3f, 56%	12	3l, 78%

^cPCy₃ was used. ^dPd(OAc)₂ (10 mol%) and PPh₃ (20 mol%) were used.

^aConditions: imidazo[1,5-*a*]pyridine **1** (0.4 mmol), aryl bromide **4** (1.05 equiv), Pd(OAc)₂ (5 mol%), PPh₃ (10 mol%), Bu₄NOAc (2 equiv), toluene (1 mL), 100 °C.

^b Isolated yield.